Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

25. september 2026 opdateret af: Vertex Pharmaceuticals Incorporated

A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

148

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Montreal, Canada
        • Rekruttering
        • Altasciences - Beaumont Clinic Montreal

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 50 år (Voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Key Inclusion Criteria:

  • Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m^2), inclusive
  • A total body weight of greater than (>) 50 kg

Key Exclusion Criteria:

  • History of febrile illness within 5 days before the first dose of study drug
  • Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug

Other protocol defined Inclusion/Exclusion criteria will apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part A: VX-407 With Levonorgestrel/Ethinyl Estradiol (LNG/EE)

Participants will receive a single dose of LNG/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 every 12 hours (q12h) from Days 8 through 26 in fasted state.

Tablets for Oral Administration.

Combination Tablets for Oral Administration.

Eksperimentel: Part B (Optional): VX-407 With Norgestimate/Ethinyl Estradiol (NGM/EE)

Participants will receive a single dose of NGM/EE on Days 1 and 23 in fasted state. Participants will also receive VX-407 q12h from Days 10 through 30 in fasted state.

Tablets for Oral Administration.

Combination Tablets for Oral Administration.

Eksperimentel: Part C (Optional): VX-407 With Norethindrone/Ethinyl Estradiol (NET/EE)

Participants will receive a single dose of NET/EE on Days 1 and 19 in fasted state. Participants will also receive VX-407 q12h from Days 6 through 22 in fasted state.

Tablets for Oral Administration.

Combination Tablets for Oral Administration.

Eksperimentel: Part D (Optional): VX-407 With Drospirenone/Ethinyl Estradiol (DRSP/EE)

Participants will receive a single dose of DRSP/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 q12h from Days 8 through 26 in fasted state.

Tablets for Oral Administration.

Combination Tablets for Oral Administration.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Part A: Maximum Observed Plasma Concentration (Cmax) of LNG/EE in the Absence and Presence of VX-407
Tidsramme: From Day 1 up to Day 7 and Day 21 up to Day 27
From Day 1 up to Day 7 and Day 21 up to Day 27
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
Tidsramme: From Day 1 up to Day 9 and Day 23 up to Day 31
From Day 1 up to Day 9 and Day 23 up to Day 31
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of NET and EE in the Absence and Presence of VX-407
Tidsramme: From Day 1 up to Day 5 and Day 19 up to Day 23
From Day 1 up to Day 5 and Day 19 up to Day 23
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of DRSP and EE in the Absence and Presence of VX-407
Tidsramme: From Day 1 up to Day 7 and Day 21 up to Day 27
From Day 1 up to Day 7 and Day 21 up to Day 27
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG/EE in the Absence and Presence of VX-407
Tidsramme: From Day 1 up to Day 7 and Day 21 up to Day 27
From Day 1 up to Day 7 and Day 21 up to Day 27
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407
Tidsramme: From Day 1 up to Day 9 and Day 23 up to Day 31
From Day 1 up to Day 9 and Day 23 up to Day 31
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of NET and EE in the Absence and Presence of VX-407
Tidsramme: From Day 1 up to Day 5 and Day 19 up to Day 23
From Day 1 up to Day 5 and Day 19 up to Day 23
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of DRSP and EE in the Absence and Presence of VX-407
Tidsramme: From Day 1 up to Day 7 and Day 21 up to Day 27
From Day 1 up to Day 7 and Day 21 up to Day 27

Sekundære resultatmål

Resultatmål
Tidsramme
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: From Day 1 up to Day 36
From Day 1 up to Day 36
Part B (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: From Day 1 Up to Day 39
From Day 1 Up to Day 39
Part C (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: From Day 1 up to Day 32
From Day 1 up to Day 32
Part D (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: From Day 1 up to Day 36
From Day 1 up to Day 36
Part A: Maximum Observed Plasma Concentration (Cmax) of VX-407
Tidsramme: Days 9, 15 and 21 up to Day 27
Days 9, 15 and 21 up to Day 27
Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tidsramme: Days 11, 17 and 23 up to Day 31
Days 11, 17 and 23 up to Day 31
Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tidsramme: Days 7, 13 and 19 up to Day 23
Days 7, 13 and 19 up to Day 23
Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407
Tidsramme: Days 9, 15 and 21 up to Day 27
Days 9, 15 and 21 up to Day 27
Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tidsramme: Days 9, 15 and 21 up to Day 27
Days 9, 15 and 21 up to Day 27
Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tidsramme: Days 11, 17 and 23 up to Day 31
Days 11, 17 and 23 up to Day 31
Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tidsramme: Days 7, 13 and 19 up to Day 23
Days 7, 13 and 19 up to Day 23
Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407
Tidsramme: Days 9, 15 and 21 up to Day 27
Days 9, 15 and 21 up to Day 27

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. september 2026

Primær færdiggørelse (Anslået)

11. marts 2027

Studieafslutning (Anslået)

20. marts 2027

Datoer for studieregistrering

Først indsendt

25. august 2026

Først indsendt, der opfyldte QC-kriterier

25. august 2026

Først opslået (Faktiske)

28. august 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

30. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

25. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • VX26-407-014

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .